Complizen Learn

Quick answer: Most mobile health apps do not need FDA authorization. Fitness tracking, meditation, nutrition logging, and other general wellness tools are typically not regulated, as long as they avoid disease-specific diagnostic or treatment claims. Apps are more likely to be regulated as medical devices when they have a medical intended use, for example diagnosing disease, treating or preventing medical conditions, analyzing medical images or signals (ECG, EEG, imaging), or

Software as a Medical Device (SaMD) is software intended for one or more medical purposes that performs those purposes without being part of a hardware medical device (IMDRF definition used by FDA). SaMD typically runs on general-purpose platforms like phones, tablets, PCs, or cloud servers. If your software’s intended use is to diagnose, treat, mitigate, cure, prevent disease, or drive clinical decision-making, it may be regulated as a medical device unless it fits an exclus

Quick answer: Your FDA medical device classification (Class I, II, or III) is based on risk and the controls needed to assure safety and effectiveness. You can usually find it by searching FDA’s Product Classification resources, then confirming the regulation number (21 CFR 862–892) and product code (3-letter code) that match your intended use and technology. FDA has classified over 1,700 generic device types across 16 medical specialty panels. Classification drives your like

FDA establishment registration tells FDA where medical devices are made or processed (for example manufacturing, sterilization, relabeling, repacking) and carries an annual establishment registration fee of $11,423 for FY2026. Device listing tells FDA which devices are associated with that establishment, and when applicable it includes the relevant premarket reference such as a 510(k), De Novo, PMA, or an exemption status. Annual registration must be submitted each year betwe

AI tools can speed up specific parts of FDA medical device regulatory work, especially first-pass predicate research, guidance discovery, requirements checklists, gap spotting, and first-draft writing. The biggest risk is accuracy: general-purpose LLMs can generate confident text with false facts or hallucinated citations, so you should treat them as drafting and research assistants, not as sources of truth. Specialized regulatory platforms like Complizen reduce verification

Biocompatibility testing evaluates whether a patient-contacting medical device could cause adverse biological responses. ISO 10993-1 provides a risk-management framework: categorize the device by nature of body contact (surface, external communicating, implant) and contact duration (limited ≤24 hours, prolonged >24 hours to 30 days, long-term >30 days), then justify the relevant biological endpoints based on the FDA/ISO tables and your risk assessment. Cytotoxicity, sensitiza

International medical device manufacturers often run into the same avoidable U.S. market-entry mistakes: assuming CE-mark experience will translate cleanly to FDA, choosing the wrong predicate strategy, trying to reuse EU clinical data without reframing it for substantial equivalence, misunderstanding when a U.S. Agent is needed, missing U.S.-specific testing expectations, underestimating the burden of Additional Information requests, overlooking remaining QMSR gaps after ISO

Sometimes. FDA may accept clinical data generated outside the United States, including data first collected for CE-marking work, in a 510(k) submission, but only if the study is well designed, well conducted, compliant with FDA’s foreign clinical data requirements under 21 CFR 812.28, and relevant to the U.S. substantial-equivalence case. The key issue is not whether the data came from Europe. It is whether the study supports the predicate-based questions FDA is actually aski

CE Mark and FDA 510(k) are separate regulatory pathways for medical device market access. CE Mark certification demonstrates compliance with the European Union Medical Device Regulation (EU MDR 2017/745), granting sales rights across 30 European Economic Area countries. FDA 510(k) clearance proves substantial equivalence to predicate devices under US regulations, enabling United States market access only. Key differences: CE Mark requires Notified Body certification for Class

Every international medical device manufacturer must appoint a US Agent before importing products into the United States. The US Agent acts as FDA's communication point for your foreign establishment and is required for FDA Establishment Registration—which you cannot complete without one. Without a registered US Agent, you cannot legally import medical devices into the US, regardless of device class or regulatory pathway (510(k), De Novo, or PMA). A US Agent must be a person

Reduce medical device clinical trial costs by 40-60% through strategic FDA engagement and smart study design. The #1 cost saver: Pre-Sub meeting ($50K investment) clarifies whether FDA will accept single-arm vs RCT, smaller patient counts, or shorter followup—potentially saving $2M-$5M before you commit to trial design. Other high-impact strategies: use single-arm design when FDA accepts objective endpoints (cuts costs 40-50% vs RCT), optimize site count to 5-8 sites (vs 15-2

Medical device clinical trials vary widely in cost depending on device risk class, study design, patient count, duration, and endpoints . Typical total budgets range from ≈$1 M to $20 M+ for studies supporting regulatory submissions – with higher budgets common for large pivotal trials. Per-participant costs for device studies often range from about $14,000 to $50,000+ per enrolled patient depending on complexity and follow-up. Many companies overspend because they assume c

Choose your sterilization method based on material compatibility first , then regulatory precedent, cost, and timeline . Ethylene oxide (EO) is the most widely used method across medical devices and works for many complex, low-temperature materials, but total turnaround often takes 1–3 weeks including aeration. Steam sterilization is the fastest and least expensive , but only suitable for heat- and moisture-stable devices. Gamma radiation is effective for some polymers but c

For most Class II medical devices cleared through the 510(k) pathway , companies should plan for multiple years from concept to commercial launch , not months. While every product is different, 18–36 months is a common planning range once design complexity, testing, and regulatory realities are accounted for. FDA does not publish end-to-end “time-to-market” timelines. Delays usually come from underestimating development effort, testing lead times, and regulatory iteration ,

FDA expects performance testing that demonstrates your device functions as intended and does not raise different questions of safety or effectiveness compared to your predicate. The scope of testing depends on device type, risk, and technological differences, but most 510(k)s include bench or performance testing , software validation where applicable , and biocompatibility assessment for patient-contacting components . This guide shows you exactly which tests FDA requires for

If FDA disagrees with your predicate choice, you'll get an Additional Information (AI) request or a Not Substantially Equivalent (NSE) determination. AI requests often add months and require either: (1) switching to a different predicate, (2) providing stronger substantial equivalence rationale, or (3) withdrawing and refiling. Not Substantially Equivalent (NSE) determination usually means you must submit new 510(k) with different predicate or pursue De Novo. This guide walks

Human Factors Engineering (HFE), also called usability engineering, is how FDA expects you to show that intended users can operate your device safely and effectively in the intended use environment, especially when use error could cause harm. For many higher-risk device types, FDA often expects human factors data in 510(k)s and PMAs, and it is common to see it in De Novo programs when the user interface drives risk. If you change a user interface in a way that can affect comp

A 510(k) submission costs between $50,000 and $250,000+ depending on device complexity, testing requirements, and whether you use consultants. Core costs include FDA user fees ($6,517-$26,067), testing/validation ($20,000-$150,000+), consultant fees ($15,000-$50,000), and establishment registration ($11,423). Most startups underestimate by 40-60%, with hidden costs from AI requests, design changes, and regulatory delays adding $30,000-$100,000+ to initial budgets. You've bui

FDA 510(k) submissions most often stumble on preventable issues: incomplete or non-compliant admin packets at Refuse to Accept (RTA) review, weak or inconsistent device descriptions and indications for use, poor predicate selection, missing or insufficient testing data, and failure to follow device-specific FDA guidance. Historically, RTA refusal rates have climbed as high as ~60% of new 510(k)s, and even in recent years roughly one-third of submissions hit an RTA hold at lea

A medical device regulatory strategy is your comprehensive plan for achieving FDA clearance or approval. It includes device classification, pathway selection (510(k), De Novo, or PMA), resource planning (team, budget, consultants), timeline mapping, testing strategy, and risk mitigation. Build it during concept phase—before design freeze or testing begins—to avoid expensive mistakes and accelerate market entry. Companies that build regulatory strategy during concept phase mak